Table 4.
Quantitation of tumor and liver uptake of 86Y-CHX-A"-panitumumab F(ab')2 by PET imaging.
| Time post-injection (h) | ||||
|---|---|---|---|---|
| Protein dose | Blocked | Organ | 24 | 48 |
| 3 μg | No | Tumor | 20.31 ± 1.52a | 22.59 ± 1.51 |
| Liver | 12.98 ± 0.95 | 11.68 ± 0.43 | ||
| Yes | Tumor | 11.37 ± 0.58 | 9.92 ± 0.66 | |
| Liver | 12.34 ± 0.99 | 12.95 ± 0.88 | ||
| 15 μg | No | Tumor | 20.30 ± 1.01 | 22.98 ± 0.84 |
| Liver | 13.84 ± 0.5 | 11.62 ± 1.12 | ||
| Yes | Tumor | 11.44 ± 0.69 | 11.38 ± 0.96 | |
| Liver | 12.60 ± 0.70 | 10.66 ± 0.57 | ||
The values presented are the percentage of injected dose per cubic centimeter. Receptor-mediated uptake of 86Y-CHX-A"-panitumumab F(ab')2 of LS-174T tumor xenografts and normal organs 2 days post-injection of the RIC. Data represent the mean ± SEM from at least three determinations. The specific activity of the 86Y- CHX-A"-panitumumab F(ab')2 was lowered by the addition of 15 μg of panitumumab F(ab')2.